The Journal of Urology
Volume 172, Issue 6, Part 1 , Pages 2426-2433, December 2004

PHYTOESTROGENS DERIVED FROM BELAMCANDA CHINENSIS HAVE AN ANTIPROLIFERATIVE EFFECT ON PROSTATE CANCER CELLS IN VITRO

From the Department of Surgery, Mater Misericordiae University Hospital, Conway Institute of Biomolecular and Biomedical Research, Dublin Molecular Medicine Centre, University College Dublin (CM, DG, JMF, RWGW), Dublin, Ireland, Bionorica AG (BS, VC), Neumarkt, Germany, and Department of Urology, University Hospital Innsbruck (JB, HK), Innsbruck, Austria

ABSTRACT 

Purpose

Phytoestrogens are nonsteroidal plant derived compounds with estrogenic activity that have been implicated in protecting against prostate cancer progression. We hypothesized that these compounds would alter cell number and increase the ability of antiandrogens to induce cell death in prostate cancer cells.

Materials and Methods

RWPE-1, LNCaP and PC-3 cells were treated with or without an extract of Belamcanda chinensis, 2 purified phytoestrogens derived from this extract (irigenin and tectorigenin) and the antiandrogen bicalutamide. We assessed the effect on cell number, proliferation and apoptosis.

Results

Phytoestrogens (50 to 100 μM) and bicalutamide (10 to 50 μM) alone decreased the cell number in all 3 cell lines. Phytoestrogens (50 μM) combined with bicalutamide (10 μM) further decreased the number of RWPE-1 and PC-3 cells compared to these agents alone. Tectorigenin and irigenin inhibited the proliferation of RWPE-1, LNCaP and PC-3 cells, causing G1 arrest and the induction of p21 (WAF1) or p27kip1 protein expression, whereas bicalutamide induced apoptosis in a dose dependent manner in all 3 cell lines. Phytoestrogens did not have antiandrogenic activity.

Conclusions

These in vitro studies demonstrate a role for tectorigenin and irigenin in regulating prostate cancer cell number by inhibiting proliferation through cell cycle regulation.

Key Words::  prostate , prostatic neoplasms , bicalutamide , phytoestrogens

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Accepted for publication June 4, 2004.Supported by Euroestrogenes Grant Contract QLK6-CT-2000-00565.

PII: S0022-5347(05)61431-0

doi:10.1097/01.ju.0000143537.86596.66

The Journal of Urology
Volume 172, Issue 6, Part 1 , Pages 2426-2433, December 2004